AzTrials
AzTrials

Atrial FibrillationCLENCT03223207

CareLink Express (CLE Research)

An observational study of Atrial Fibrillation, run by Baylor Research Institute.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The primary objective of this research is to determine if evaluating CIEDs using CareLink Express® can lead to shorter time to interrogation in the Emergency Department compared to evaluation of devices using traditional evaluation procedures. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Atrial Fibrillation
How many people
60 participants
Where
No sites listed yet
Study dates
Mar 2016to 27 Aug 2018
How long will I take part?
1 Day
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients who arrive to the Emergency Department with a problem they presume to be cardiac in nature.

Who may be able to join

  • 1) Patients who present to the ED with a problem they believe to be cardiac in nature.

Who cannot join

  • Patients who present to the ED after transmitting a remote device evaluation within the last 24 hours.
  • Patients referred to the ED from a physician's office or other health care facility where the CIED has already been interrogated or evaluated.
  • Patients in cardiac arrest or other life threatening situations.

About this study

The primary objective of this research is to determine if evaluating CIEDs using CareLink Express® can lead to shorter time to interrogation in the Emergency Department compared to evaluation of devices using traditional evaluation procedures. The goal of the research is to determine if patients evaluated by CareLink Express® have a reduction of "time to interrogation" compared to the traditional patient cohort.

Secondary objectives of the study are to determine any significant differences in the two populations regarding:

  1. Health care resource utilization including total charges for ED care.
  2. Number of patients leaving the ED without being seen (LWBS) or left without the device interrogation completed.
  3. Device related issues detected.
Read the detailed description

Background:

Over the past 15 years the number of Cardiac Implantable Electronic Devices (CIEDs) implanted has increased dramatically. This is due in part to the aging of the population in general, but primarily due to expanded indications for implantable cardioverter-defibrillators (ICDs), cardiac resynchronization pacemaker therapy (CRT-P) devices, and CRT devices with defibrillator capabilities ("biventricular ICDs" or CRT-D devices). As more patients with structural heart disease survive longer, and as more CIEDs are placed, the number of patients requiring treatment in the emergency departments for arrhythmias and potential device-related matters has increased.

When a patient with a CIED experiences a problem they presume to be cardiac in nature, they often go to the emergency room to seek care. Most emergency departments (ED) are neither equipped to interrogate the CIED, nor staffed with personnel trained to interrogate the CIED. These CIEDs often record data that can assist the physician in the formulation of a diagnostic and treatment strategy tailored to the specific needs of the patient. However, interrogation of the device is dependent on proprietary programming equipment that is not routinely kept in the emergency department. The programming equipment has traditionally been a "stand-alone" unit, which can store the data from the device interrogation (onto a USB drive or floppy disk), but does not have the capability to transmit the data to the patient's physician for rapid interpretation. In addition, ED personnel are not routinely trained to assess CIEDs. In most health care institutions, it is standard practice for a representative of the manufacturer to be contacted so the device can be evaluated. The representative must then travel to the ED with the programming equipment to interrogate the CIED on site. After interrogation, either the representative discusses the findings with the ED physician, or calls the physician that manages the patient's device. The process of in-person device evaluation can be cumbersome and inefficient, especially in an emergency setting. The time involved in the device interrogation process can cause delays in patient care and add unnecessary costs for the patient and health care institution.

Methods:

Patients with CIEDs will be evaluated in the ED setting. Patients will be divided into two cohorts. Each cohort will have a minimum of 50 patients.

The control group will include CIED patients who have been evaluated in the ED at The Heart Hospital Baylor Plano and Baylor Regional Medical Center at Plano. A minimum of 50 devices not compatible with the CareLink Express® system will be prospectively interrogated in the traditional evaluation method using the device manufacturer representative.

The study group will include CIED patients who present to the ED and receive a device evaluation using the CareLink Express® system. A minimum of 50 devices will be prospectively evaluated using CareLink Express®.

The patient's presenting symptoms in the ED include any medical conditions (not just cardiac).

Consent will be obtained from the subject after treatment has occurred in the ED and prior to release. Consent can be obtained from the subject or the subject's Legally Authorized Representative. This will ensure that treatment is not delayed or altered for research purposes.

Initial data will be collected using a Data Collection Form. The research staff or a research trained Emergency Department staff member will complete the Data Form.

Data will be collected by the research coordinators who will collect the Data Collection Forms from the ED at The Heart Hospital Baylor Plano and Baylor Regional Medical Center at Plano. The Data Collection Form will be used by the research coordinators to determine the patient's study cohort.

Other data will be collected by the research coordinators using the hospital EMR and Financial systems.

Data Collection:

Criteria for the hospital and ED encounters will be extracted from the hospital EMR, the Data Collection Form, or the hospital financial system. Device data will be extracted from the device report completed at the time of the device interrogation.

Medical subject headings
Atrial Fibrillation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT03223207
Study groupRoleWhat they receive
Control GroupThe control group will include CIED patients who have been evaluated in the ED at The Heart Hospital Baylor Plano and Baylor Regional Medical Center at Plano. A minimum of 50 devices not compatible with the CareLink Express® system will be prospectively interrogated in the traditional evaluation method using the device manufacturer representative.
CareLink ExpressThe study group will include CIED patients who present to the ED and receive a device evaluation using the CareLink Express® system. A minimum of 50 devices will be prospectively evaluated using CareLink Express®.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Patients evaluated by CareLink Express have a reduction of "time of interrogation" compared to the traditional patient cohort.

    The primary objective of this research is to determine if evaluating CIEDs using CareLink Express® can lead to shorter time to interrogation in the Emergency Department compared to evaluation of devices using traditional evaluation procedures.

    Measured: 1 year

Secondary outcomes (1)
  1. Significant differences between the two populations from data analysis

    Health care resource utilization including total charges for ED care, number of patients leaving the ED without being seen (LWBS) or left without the device interrogation completed, or device related issues detected.

    Measured: 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Jul 2017
  2. Study startMar 2016
  3. Primary completion27 Aug 2018
  4. Study completion27 Aug 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
60 participants (actual)
Target duration
1 Day
IDs, dates and publications
ClinicalTrials.gov ID
NCT03223207
Sponsor's protocol ID
015-234
Acronym
CLE
Status last verified
Jul 2017
First submitted
25 Feb 2016
Last updated
22 May 2019
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

An observational study of Atrial Fibrillation, run by Baylor Research Institute.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 May 2019. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Patients evaluated by CareLink Express have a reduction of "time of interrogation" compared to the traditional patient cohort. (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2019.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in